3 February 2026
US Congress passes bill that reauthorises the FDA's paediatric priority voucher pathway for five more years
The rare pediatric disease priority review voucher pathway is reauthorised for five more years.
3 February 2026
The rare pediatric disease priority review voucher pathway is reauthorised for five more years.